R Squared’s Rocket Pharmaceuticals RCKT Stock Holding History

R Squared’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-300	Closed	-$3.77K	–	1211
2024 Q4	$3.77K	Buy	+300	New	+$4.52K	﹤0.01%	1373

Other funds holding RCKT

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

R Squared's RCKT Position: Q1 2025 in Review

R Squared sold out of Rocket Pharmaceuticals (RCKT) in Q1 2025, closing a stake of 300 shares — an estimated $3.77K sold.

R Squared first reported a position in RCKT in Q4 2024 and held it in 1 quarter. The position peaked at $3.77K in Q4 2024. 236 funds tracked by Wall St. Rank hold RCKT as of Q1 2025.

R Squared reported no remaining Rocket Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
R Squared sold 300 Rocket Pharmaceuticals shares in Q1 2025, an estimated $3.77K.
R Squared first reported a position in Rocket Pharmaceuticals in Q4 2024 and held it in 1 quarter.
R Squared's Rocket Pharmaceuticals position peaked at $3.77K in Q4 2024.
236 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.